Dr. Barbara T. Ma, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- New York Medical College (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 126
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: New York Medical College
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 292800
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
Medical groups
- Weill Medical College of Cornell (2,051 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 126
- Services billed
- 34,039
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 149 | 57 |
| Established patient office or other outpatient visit, 30-39 minutes | 72 | 41 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 68 | 35 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 21 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Triamcinolone Acetonide Other prescribers in New York, NY | 13 |
| Famotidine Other prescribers in New York, NY | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 8 payments worth $2,859 in total to this clinician.
| Iovance Biotherapeutics, Inc. | $2,816 |
|---|---|
| Ipsen Biopharmaceuticals, Inc | $27.26 |
| Array Biopharma Inc | $16.11 |
| Honoraria | $2,400 |
|---|---|
| Travel and Lodging | $250 |
| Food and Beverage | $209 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Iovance Biotherapeutics, Inc. Jun 5, 2025 | Honoraria Amtagvi · Oncology | $2,400 |
| Iovance Biotherapeutics, Inc. Jun 6, 2025 | Travel and Lodging Amtagvi · Oncology · travel to Chicago, IL | $250 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $6,278 in research payments for these studies, mostly to the institutions running them.
- Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
Daiichi Sankyo Inc. · Completed · NCT04484142
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.